Browsing Tag
WCBP 2025
2 posts
Why did Newron Pharmaceuticals stock rise by nearly 8% and what triggered investor enthusiasm?
Newron Pharmaceuticals stock rallies 7.88% after evenamide schizophrenia trial data and WCBP presentations highlight breakthrough potential. Read what’s next for investors.
Can evenamide become the first real breakthrough for treatment-resistant schizophrenia?
Newron Pharmaceuticals reveals evenamide data at WCBP 2025, showcasing new hope for treatment-resistant schizophrenia through glutamate modulation.